Curriculum Vitae

ALAN M. GARBER





Mailing Address: PCOR/CHP

179 Encina Commons

Stanford University

Stanford, California 94305-6019

Telephone: 650/723-0920

Facsimile number: 650/724-5182

Electronic mail: garber@stanford.edu



Year of Birth: 1955

Place of Birth: Illinois



Education:

1973-76 Harvard College, Cambridge, Massachusetts, A.B. (Economics)

1976-77 Harvard University, Cambridge, Massachusetts, A.M. (Economics)

1977-82 Harvard University, Cambridge, Massachusetts, Ph.D. (Economics)

1977-83 Stanford University School of Medicine, Stanford, California, M.D.

Clinical Training:



1983-86 Internship and Residency in Medicine, Brigham and Women's Hospital, Boston, Massachusetts



Academic Appointments:



1983-86 Clinical Fellow in Medicine, Harvard Medical School

1986 Christopher Walker Research Fellow, Center for Health Policy and Management, John F. Kennedy School of Government, Harvard University

1986-93 Assistant Professor of Medicine, Division of General Internal Medicine, Stanford University School of Medicine

1986-93 Assistant Professor, by courtesy, Department of Economics, Stanford University

1988-93 Assistant Professor, by courtesy, Department of Health Research and Policy, Stanford University School of Medicine

1993-98 Associate Professor of Medicine (tenured), Division of General Internal Medicine, Stanford University School of Medicine

1993-98 Associate Professor, by courtesy, Department of Economics and Department of Health Research and Policy, Stanford University

1997- Senior Fellow, Institute for International Studies, Stanford University

1998- Henry J. Kaiser, Jr. Professor

Professor of Medicine

Professor of Economics, by courtesy, and Professor of Health Research and Policy, by courtesy, Stanford University

1999- Professor of Economics, by courtesy, in the Graduate School of Business, Stanford University



Hospital Appointments:



1986- Staff Physician, Department of Veterans Affairs Palo Alto Health Care System (formerly Palo Alto VA Medical Center)

1991-94 Chair, Pharmacy and Therapeutics Committee, Palo Alto VA Medical Center



Other Professional Positions:



1979-82 Research Analyst, National Bureau of Economic Research. Dissertation research on "Costs and Control of Antibiotic Resistance." Thesis advisors: Martin Feldstein, Professor of Economics, Harvard University; Zvi Griliches, Professor of Economics, Harvard University; and Richard J. Zeckhauser, Professor of Political Economy, Kennedy School of Government, Harvard University



1979-80 Consultant, Division of Health Promotion and Disease Prevention, Institute of Medicine of the National Academy of Sciences. Professional staff for the Committee for the Planning Study for Ongoing Study of the Costs of Environment-Related Health Effects (chaired by Kenneth Arrow, Professor of Economics and Professor of Operations Research, Stanford University)



1983-86 Faculty Research Fellow, National Bureau of Economic Research



1986- Research Associate, National Bureau of Economic Research



1987- Acting Director (1987-88), Co-director (1988-90), and Director (1990 to date), Health Care Research and Policy Fellowship, Stanford University



1987-96 Director, Palo Alto VA Medical Center component, UCSF/Stanford Robert Wood Johnson Clinical Scholars Program



1988-89, Contractor, Office of Technology Assessment, U.S. Congress

1991-92



1988- Associate Director, Center for Health Care Evaluation: VA HSR&D Field Program, Department of Veterans Affairs



1990- Director, Health Care Program, National Bureau of Economic Research



1991-95 Deputy Director, Comparative Health Care Policy Research Project, Asia/Pacific Research Center, Stanford University



1992-96 Fellow, Asia/Pacific Research Center, Stanford University



1992-93 Fellow, Center for Advanced Study in the Behavioral Sciences

1993-95 Member, Panel on Cost-Effectiveness in Health and Medicine (formerly Cost-Effectiveness Panel on Clinical Preventive Services), Office of Disease Prevention and Health Promotion, Department of Health and Human Services



1993- Member, Medical Advisory Panel, Blue Cross and Blue Shield Association



1994 Acting Chief, General Internal Medicine, Palo Alto VA Medical Center



1994-95 Acting Chief, Division of General Internal Medicine, Stanford University School of Medicine



1994-96 Fellow, McKinsey Global Institute



1994-96 Associate Editor, Journal of Investigative Medicine

1994-98 Member, Social Sciences and Population Study Section, Division of Research Grants, National Institutes of Health



1997- Associate Editor, Health Services Research



1997- Editorial Board, American Journal of Medicine



1997- Director, Center for Primary Care and Outcomes Research, Stanford University School of Medicine

Director, Center for Health Policy, Stanford University

1998-2000 The Robert Wood Johnson Foundation Scholars in Health Policy Research Program National Advisory Committee



1999-2003 Chairperson, Medical and Surgical Procedures Panel, Medicare Coverage Advisory Committee



2001-2004 Editorial Board, Annals of Internal Medicine



Awards and Honors:



1976 A.B. degree summa cum laude, Harvard College

1976 Phi Beta Kappa

1976 John Harvard Scholarship

1976-77, 79-81 National Science Foundation Graduate Fellowship (Economics)

1980-81 National Center for Health Services Research, Dissertation Grant

1983 Research Honors Award, Stanford University School of Medicine

1989-92 Henry J. Kaiser Family Foundation Faculty Scholar in General Internal Medicine

1991-97 HSR&D Senior Research Associate, Department of Veterans Affairs

1992 Young Investigator Award, Association for Health Services Research

1996 Fellow, Association for Health Services Research

1998 American Society for Clinical Investigation

1998 Member, Institute of Medicine of the National Academy of Sciences





Professional Societies:



American Federation for Clinical Research (Stanford Councilor, 1989-91; National Councilor, 1991-96; AFCR representative, Long-range Planning Committee, 1992-93)

Society of General Internal Medicine

Society for Medical Decision Making (Trustee, 1989-91)

American Economic Association

American College of Physicians (Advanced to Fellowship, 1990)

Association for Health Services Research

Institute of Mathematical Statistics

Western Society for Clinical Investigation (Elected 1992)



PUBLICATIONS



Articles:



1. Garber AM, Fuchs VR, Silverman, JF. Case mix, costs, and outcomes: differences between faculty and community services in a university hospital. New England Journal of Medicine 310:1231-1237, 1984.



2. Garber AM. Antibiotic exposure and resistance in mixed bacterial populations. Theoretical Population Biology 32:326-346, 1987.



3. Garber AM. Cost-containment and financing the long-term care of the elderly. Journal of the American Geriatrics Society, 36:355-361, 1988.



4. Garber AM, Sox HC, Littenberg B. Screening asymptomatic adults for cardiac risk factors: the serum cholesterol level. Annals of Internal Medicine, 110:622-39, 1989. Reprinted in Eddy DM, editor, Common Screening Tests, pp. 113-153. Philadelphia: American College of Physicians, 1991.



5. Sox HC, Littenberg B, Garber AM. The role of exercise testing in screening for coronary artery disease. Annals of Internal Medicine, 110:456-69, 1989. Reprinted in Eddy DM, editor, Common Screening Tests, pp. 81-112. Philadelphia: American College of Physicians, 1991.



6. Sox HC, Garber AM, Littenberg B. The resting electrocardiogram as a screening test: a clinical analysis. Annals of Internal Medicine, 111:489-502, 1989. Reprinted in Eddy DM, editor, Common Screening Tests, pp. 47-80. Philadelphia: American College of Physicians, 1991.



7. Garber AM. Where to draw the line against cholesterol. (Editorial). Annals of Internal Medicine, 111:625-27, 1989.



8. Garber AM. A discrete-time model of the acquisition of antibiotic-resistant infections in hospitalized patients. Biometrics, 45:797-816, 1989.



9. Littenberg B, Garber AM, Sox HC. Screening for hypertension. Annals of Internal Medicine, 112:192-202, 1990. Reprinted in Eddy DM, editor, Common Screening Tests, pp. 22-46. Philadelphia: American College of Physicians, 1991.



10. Fuchs VR, Garber AM. The new technology assessment. New England Journal of Medicine, 323:673-677, 1990.



11. Polaschek JX, Lenert LA, Garber AM. A computer program for statistically-based decision analysis, pp 795-99, Proceedings of the Symposium on Computer Applications in Medical Care. Washington, D.C., 1990.



12. Garber AM, Fenerty JP. Costs and benefits of prenatal screening for cystic fibrosis. Medical Care, 29:473-489, 1991.



13. Garber AM, Littenberg B, Sox HC, Wagner JL, Gluck M. Costs and health consequences of cholesterol screening for asymptomatic older Americans. Archives of Internal Medicine, 151:1089-1095, 1991.



14. Garber AM, Wagner JL. Practice guidelines and cholesterol policy. Health Affairs, 10:52-66, 1991.



15. Garber AM. No price too high? (Editorial). New England Journal of Medicine, 327:1676-78, 1992.



16. Goldman DP, Clarke AE, Garber AM. Creating the costliest orphan: the Orphan Drug Act in the development of Ceredase. International Journal of Technology Assessment in Health Care, 8:583-597, 1992.



17. Hornberger JC, Chernew M, Garber AM, Petersen J: A multivariate analysis of

mortality and hospital admission rates of high-flux dialysis. Journal of the American Society of Nephrology, 3:1227-1237, 1992.



18. Hulley SB, Newman TB, Grady D, Garber AM, Baron RB, Browner WS. Should we be measuring blood cholesterol levels in young adults? Journal of the American Medical Association, 269:1416-1419, 1993.



19. Hornberger JC, Garber AM, Chernew M: Is high-flux dialysis cost effective? International Journal of Technology Assessment in Health Care, 9:85-96, 1993.



20. Garber AM, MaCurdy T. Nursing home discharges and exhaustion of Medicare benefits. Journal of the American Statistical Association, 88:727-736, 1993.



21. Garber AM. Benefits vs. profits: has the Orphan Drug Act gone too far? Pharmacoeconomics, 5:88-92, 1994.



22. Garber AM, Olshen RA, Zhang H, Venkatraman ES. Predicting high-risk cholesterol levels.  International Statistical Review, 62:203-228, 1994. Previous version available as Technical Report No. 151, Division of Biostatistics, Stanford University, 1992.



23. Garber AM, Avins AL. Triglyceride concentration and coronary heart disease (editorial). British Medical Journal, 309:2-3, 1994.



24. Garber AM. Can technology assessment control health spending? Health Affairs, 13:115-126, 1994.



25. Beutler E, Garber AM. Alglucerase for Gaucher's Disease: dose, costs, and benefits. PharmacoEconomics, 5:453-459, 1994.



26. Goldstein MK, Clarke AE, Michelson D, Garber AM, Bergen MR, Lenert LA. Developing and testing a multimedia presentation of a health state description. Medical Decision Making, 14:336-344, 1994.



27. Weinstein MC, Garber AM, Fryback DG. Workshop J: Prevention strategies, economic realities, and identification of prevention research needs. Preventive Medicine, 23:571-572, 1994.



28. Newman TB, Garber AM, Holtzman NA, Hulley SB. Problems with the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Archives of Pediatric and Adolescent Medicine, 149:241-247, 1995.



29. Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Annals of Internal Medicine, 124:518-31, 1996.



30. Garber AM, Browner WS for the American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglycerides as screening tests for preventing coronary heart disease in adults. Annals of Internal Medicine, 124:515-17, 1996.



31. Owens DK, Holodniy M, Garber AM, Scott J, Sonnad S, Moses L, Kinosian B, Schwartz JS. Polymerase chain reaction for the diagnosis of HIV infection in adults: a meta-analysis with recommendations for clinical practice and study design. Annals of Internal Medicine, 124:803-815, 1996.



32. Goldman L, Garber AM, Grover SA, Hlatky MA. Task Force 6: Cost effectiveness of assessment and management of risk factors. Journal of the American College of Cardiology, 27:957-1047, 1996.



33. Barnett PG, Garber AM. The cost of VA-sponsored research. Academic Medicine, 71:1074-1078, 1996.



34. Garber AM. Cost-effectiveness analysis as a measure of value. Tecnologica., 39:1, 3-6, 9-10, 1996.



35. Garber AM, Romer PM. Evaluating the federal role in financing health-related research. Proceedings of the National Academy of Sciences, 93:12717-12724, 1996.



36. Lee TT, Solomon NA, Heidenreich PA, Oehlert J, Garber AM. Cost-effectiveness of screening for carotid stenosis in asymptomatic individuals. Annals of Internal Medicine, 126:337-46, 1997.



37. Garber AM. Cholesterol screening should be targeted. Am J Med 102(2A):26-30, 1997.



38. Garber AM, Browner WS. Cholesterol screening guidelines: Consensus, evidence, and common sense. Circulation, 95:1642-1645, 1997.



39. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. Journal of Health Economics, 16:1-31, 1997.



40. Hornberger JC, Garber AM, Jeffery JR. Mortality, hospital admissions, and medical costs of end-stage renal disease in the United States and Manitoba, Canada. Medical Care, 35:686-700, 1997.



41. Clarke AE, Goldstein MK, Michelson D, Garber AM, Lenert LA. The effect of assessment method and respondent population on utilities elicited for Gaucher Disease. Quality of Life Research, 6:169-184, 1997.



42. Flowers CR, Garber AM, Bergen MR, Lenert LA. Willingness-to-pay utility assessment: feasibility of use in normative patient decision support systems. Proceedings / AMIA Annual Fall Symposium. 1997;16:223-7.



43. Weinstein MC, Siegel JE, Garber AM, Lipscomb J, Luce BR, Manning WG, Torrance GW. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Economics, 6:505-510, 1997.



44. Baily MN, Garber AM. Health care productivity. Brookings Papers on Economic Activity: Microeconomics:143-202, 1997.



45. Lenert LA, Morss S, Goldstein MK, Bergen MR, Faustman WO, Garber AM. Measurement of the validity of utility elicitations performed by computerized interview. Medical Care, 35:915-20, 1997.



46. Lenert LA, Cher DJ, Goldstein MK, Bergen MR, Garber AM. The effect of search procedures on utility elicitations. Medical Decision Making, 18:76-83, 1998.



47. Garber AM. Making the most of Pap testing (editorial). JAMA, 279:240-241, 1998.



48. Brown AD, Garber AM. Cost-effectiveness of coronary heart disease prevention strategies in adults. Pharmacoeconomics,14:27-48, 1998.



49. Chen S, Shaheen A, Garber AM. Cost-effectiveness and cost benefit analysis of using methotrexate vs. Goeckerman therapy for psoriasis. Archives of Dermatology 134:1602-1608, 1998.



50. Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA 281:347-353, 1999.



51. Garber AM, Solomon NA. Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. Annals of Internal Medicine 130:719-728, 1999.



52. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low molecular weight heparins compared with unfractionated heparin for the treatment of acute deep vein thrombosis:A cost-effectiveness analysis. Annals of Internal Medicine,130:789-99, 1999.



53. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low molecular weight heparins compared with unfractionated heparin for the treatment of acute deep vein thrombosis: A meta-analysis of randomized controlled trials. Annals of Internal Medicine, 130: 800-809, 1999.



54. Garber AM. Realistic rigor in cost-effectiveness methods (comment). Medical Decision Making 19:378-379, 1999.



55. Newman TB, Garber AM. Cholesterol screening in children and adolescents (comment). Pediatrics 105: 637-28, 2000.



56. Gerson LB, Robbins AS, Garber AM, Hornberger J, Triadafilopoulos GT. A cost-effectiveness analysis of prescribing strategies in managing gastroesophageal reflux disease. American Journal of Gastroenterology 95:395-407, 2000.



57. Garber AM. Using cost-effectiveness analysis to target cholesterol reduction (editorial). Annals of Internal Medicine 132:833-835, 2000.



58. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression strategies in advanced prostate cancer. J Natl Cancer Inst 92:1731-9, 2000.

59. Hlatky MA, Saynina O, McDonald K, Garber AM, McClellan M. Utilization and outcomes of the implantable cardioverter defibrillator, 1987-1995. American Heart Journal, in press.



Books edited:



Garber AM, editor, Frontiers in Health Policy Research 1. Cambridge, MA: MIT Press, 1998.



Garber AM, editor, Frontiers in Health Policy Research 2. Cambridge, MA: MIT Press, 1999.



Garber AM, editor, Frontiers in Health Policy Research 3, Cambridge, MA: MIT Press, 2000.



Garber AM, editor, Frontiers in Health Policy Research 4, Cambridge, MA: MIT Press, in press.



Garber AM, and Ogura S, editors, Issues in Health Care in the U.S. and Japan, University of Chicago Press, in press.



Monographs and book chapters:



1. Garber AM, Costs and Control of Antibiotic Resistance. Ph.D. dissertation, Department of Economics, Harvard University, Cambridge, Massachusetts, 1982.



2. Garber AM. Long-term care, wealth, and health of the disabled elderly living in the community. In Wise DA, editor, The Economics of Aging, pp 255-77. Chicago: University of Chicago Press, 1989.



3. Garber AM, Littenberg B, Sox HC, Gluck ME, Wagner JL, Duffy BM. Costs and effectiveness of cholesterol screening in the elderly. Washington, DC: U.S. Government Printing Office, 1989 (GPO Stock Number 052-003-01151-4).



4. Garber AM. Pursuing the links between socioeconomic factors and health: critique, policy implications, and directions for future research. In Bunker JP, Gomby DS, and Kehrer BH, editors, Pathways to Health: the Role of Social Factors, pp 271-315. Menlo Park, CA: The Henry J. Kaiser Family Foundation, 1989.



5. Garber AM. Testimony on cholesterol. Cholesterol Education Program: Hearing Before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred First Congress, First Session, December 7, 1989. Serial No. 101-107, pp. 124-41. Washington, D.C.: U.S. Government Printing Office.



6. Garber AM, MaCurdy T. Predicting nursing home utilization among the high-risk elderly. In Wise DA, editor, Issues in the Economics of Aging, pp 173-200. Chicago: University of Chicago Press, 1990.



7. Garber AM, MaCurdy TE. Payment source and episodes of institutionalization. In Wise DA, editor, Topics in the Economics of Aging, pp 249-271. Chicago: University of Chicago Press, 1992.



8. Garber AM, Fuchs VR. The expanding role of technology assessment in health policy, Stanford Law & Policy Review, 3:203-209, 1991.



9. Garber AM, Clarke AE, Goldman DP, Gluck ME. Federal and private roles in the development and provision of alglucerase therapy for Gaucher Disease. OTA-BP-H-104. Washington, D.C.: U.S. Government Printing Office, October 1992.



10. Garber AM. Financing health care for elderly Americans in the 1990s. In Noguchi Y, and Wise DA, editors, Aging in the United States and Japan: Economic Trends, pp. 175-194. Chicago: University of Chicago Press, 1994.



11. Garber AM, Owens DK. Paying for evaluative research. In Gelijns AC, and Dawkins HV, editors, Medical Innovations at the Crossroads, Vol. IV: Adopting New Medical Technology, pp. 172-192. Washington, D.C.: National Academy Press, 1994.



12. Barnett PG, Garber AM. Cost of VA Sponsored Research: Modified Cost Allocation Method. Rapid Response Project prepared for the Management Decision Research Center, Department of Veterans Affairs. Center for Health Care Evaluation, Department of Veterans Affairs, January 1995.



13. Garber AM. To comfort always: prospects of expanded social responsibility for long-term care. In Fuchs VR, editor, Individual and Social Responsibility: Child Care, Education, Medical Care, and Long-Term Care in America, pp. 143-69. Chicago:University of Chicago Press, 1996.



14. Garber AM, Weinstein MC, Torrance GW, Kamlet MS. Theoretical foundations of cost-effectiveness analysis. In Gold MR, Siegel JE, Russell LB, and Weinstein MC, editors, Cost-Effectiveness in Health and Medicine, pp. 25-53. New York: Oxford University Press, 1996.



15. Dick A, Garber AM, MaCurdy T. Forecasting nursing home utilization of elderly Americans. In Wise DA, editor, Studies in the Economics of Aging, pp. 365-394. Chicago: University of Chicago Press, 1994.



16. Solomon NA, Garber AM for the Medical Advisory Panel, TEC Program, Blue Cross Blue Shield Association. Positron emission tomography myocardial perfusion imaging for the detection of coronary artery disease. 1995.



17. Garber AM, Brown AD for the Medical Advisory Panel, TEC Program, Blue Cross Blue Shield Association. Outpatient pulmonary rehabilitation for chronic obstructive lung disease-cost-effectiveness analysis. 1997.



18. Brown AD, Garber AM for the Medical Advisory Panel, TEC Program, Blue Cross Blue Shield Association. The cost-effectiveness of three new technologies to enhance Pap testing. 1998.



19. Bhattacharya J, Garber AM, MaCurdy TE. Cause-specific mortality among Medicare enrollees. In Wise DA, editor, Inquiries in the Economics of Aging, pp. 311-324. Chicago: University of Chicago Press, 1998.



20. Garber AM, MaCurdy TE, McClellan MA. Diagnosis and Medicare expenditures at the end of life. In Wise DA, editor, Frontiers in the Economics of Aging, pp. 247-273. Chicago: University of Chicago Press, 1998.



21. Garber AM, MaCurdy TE, McClellan MA. Persistence of Medicare expenditures among elderly beneficiaries . In Garber AM, editor, Frontiers in Health Policy Research 1, pp. 153-180. Cambridge, MA: MIT Press, 1998.



22. Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanceed prostate cancer. Evidence Report/Technology Assessment No. 4. (Prepared by Blue Cross/BLue Shield Association Evidence-based Practice Center under Contract NO. 290-97-0015). AHCPR Publication No. 99-EE0012. Rockville, Maryland: Agency for Health Care Policy and Research. May, 1999.



23. Garber AM, MaCurdy TE, McClellan MA. Medical care at the end of life: diseases, treatment patterns, and costs. In Garber AM, editor, Frontiers in Health Policy Research 2, pp. 77-98. Cambridge, MA: MIT Press, 1999.



24. Brown AD, Garber AM. Cost effectiveness of coronary heart disease prevention strategies in adults. In Mallarkey G, editor, Aspects of Hypertension Management, pp. 85-106. Auckland, New Zealand: Adis International Limited, 1999.



25. Brown AD, Garber AM. A concise review of the cost-effectiveness of coronary heart disease prevention. Medical Clinics of North America 84:279-297, 2000.



26. Hwang A, Brown A, Garber A. Cost-effectiveness of diagnosis and screening for coronary artery disease with electron beam computed tomography. Blue Cross-Blue Shield Association, TEC Special Assessment, 14:1-37, 2000.



27. Garber AM. Advances in cost-effectiveness analysis of health interventions. In Culyer AJ and Newhouse JP, editors, Handbook of Health Economics, Vol. 1, pp. 181-221. Amsterdam: North-Holland, 2000.



28. Singer SJ, Enthoven AC, Garber AM. Chapter 19 in "Medical Informatics: Computer Applications in Health Care and Biomedicine" (EH Shortliffe, LE Perreault, G Wiederhold, LM Fagan, eds), pp 663-696. New York: Springer-Verlag, 2000.



29. MaCurdy TE, Garber AM. Growth in expenditures for hospital care for the elderly: cohort and time effects. In Garber AM and Ogura S, editors, Issues in Health Care in the U.S. and Japan, Chicago: University of Chicago Press, forthcoming.